Objetivo
MeMed has completed development of ImmunoXpert™, an in vitro diagnostic test that leverages the body’s immune system to accurately differentiate between bacterial and viral infections. A breakthrough in infectious disease diagnosis, ImmunoXpert™ overcomes limitations of traditional diagnostics, outperforming standard of care. ImmunoXpert™ recently received regulatory European clearance (CE-IVD) and represents a close-to-market innovation. Market entry points include emergency department and hospitalized pediatric patients with respiratory tract infections (RTI) and fever without source (FWS), for which ImmunoXpert™ is uniquely positioned to improve patient management and health economics. In children, RTIs account for 50% of doctor visits and hospitalization. Fever accounts for 10-25% of pediatric ED visits, with as many as 20% without identifiable source. The global market for ImmunoXpert™ diagnosis of pediatric RTI/FWS is €2.8B (EU is €560M).
To fast track market adoption across Europe we propose:
•To transition ImmunoXpert™ from a hands-on laboratory assay to Tecan’s hands-free, rapid automated laboratory platform to increase clinical utility and economic benefit
•To roll-out ImmunoXpert™ to EU pilot hospitals with the goal of managing 1200 pediatric patients to evaluate performance and clinical utility in real working conditions
•To perform health economics analysis and establish reimbursement strategy
AutoPilot-Dx is a cross sector effort (industry, KOLs, outcome researchers) highly aligned with H2020-FTIPilot’s goals and Societal Challenges: it will reduce ImmunoXpert™’s time to market and provide a road-map for sustainable market uptake; a H2020 first-time applicant is involved; the project will enable MeMed and Tecan to scale-up in line with their business strategies; the immune-based diagnostics will improve antibiotic stewardship, providing better, personalized, care for children with RTI/FWS and help fight antibiotic resistance – a global health threat
Ámbito científico
CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural.
CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural.
- medical and health scienceshealth sciencesinfectious diseases
- social sciencessociologyindustrial relationsautomation
- medical and health sciencesbasic medicineimmunology
- social scienceseconomics and businesseconomicshealth economics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programa(s)
Régimen de financiación
IA - Innovation actionCoordinador
39120 TIRAT CARMEL
Israel
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.